Literature DB >> 32662397

Snakebites in Suriname: Evaluation of the Protocolled Administration of Anti-Snake Venom in a Tertiary Care Setting.

Navin Ramdhani1, Simone Jonker1, Kevin van 't Kruys2, Rakesh Bansie3, Wilco Zijlmans4,5.   

Abstract

Venomous snakebites regularly occur in Suriname, a middle-income country located on the north coast of South America. Officially reported data on incidence and mortality are lacking. The aim of this retrospective study was to assess whether the use of our national snakebite protocol with selective administration of anti-snake venom (ASV) in patients with signs of snakebite envenoming improved clinical outcome as measured by mortality and length of stay (LOS) in the hospital. Medical records of all patients admitted at the Academic Hospital Paramaribo from 2013 to 2015, before and after the introduction of the protocol, with signs of snakebite envenoming, were reviewed for demographics, snakebite characteristics, mortality, length of hospital stay, administration of ASV, and occurrence of complications. Secondary outcome measures were the development of late complications due to a snakebite. Sixty-eight and 76 patients in 2013 and 2015, respectively, with venomous or potentially venomous snakebites were identified. One patient (1.5%) in 2013 and 29 patients (38.2%) in 2015 received ASV. In 2013 one patient died: deterioration of renal function occurred before protocolled ASV administration. No deaths were reported in 2015. There was no difference in the overall length of hospital stay between 2013 and 2015 or in the total number of late complications. In 2015, the mean LOS (±SD) for patients who did not receive ASV (n = 47) was significantly lower than that for patients who received ASV (n = 29), 2.15 ± 2.27 versus 5.31 ± 5.53 days, respectively (P = 0.001). The mean LOS (±SD) for patients who did not receive ASV in 2013 (n = 67) and 2015 (n = 47) was 4.06 ± 5.44 and 2.15 ± 2.27 days, respectively, which also differed significantly (P = 0.025). The protocolled evaluation of snakebite victims resulted in more patients being admitted to the intensive care unit and receiving ASV and a shorter length of hospital stay for the patients who did not receive ASV, and no difference in the occurrence of complications was observed in Suriname's largest hospital responsible for the acute care of snakebite victims.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32662397      PMCID: PMC7543850          DOI: 10.4269/ajtmh.20-0144

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  18 in total

1.  Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy.

Authors:  Simon G A Brown; Ngaire Caruso; Meredith L Borland; David L McCoubrie; Antonio Celenza; Geoffrey K Isbister
Journal:  Intensive Care Med       Date:  2009-06-23       Impact factor: 17.440

Review 2.  Antivenom efficacy or effectiveness: the Australian experience.

Authors:  Geoffrey K Isbister
Journal:  Toxicology       Date:  2009-09-25       Impact factor: 4.221

3.  Toxicity of Bothrops sp snake venoms from Ecuador and preclinical assessment of the neutralizing efficacy of a polyspecific antivenom from Costa Rica.

Authors:  Johana Laines; Álvaro Segura; Mauren Villalta; María Herrera; Mariángela Vargas; Gladys Alvarez; José María Gutiérrez; Guillermo León
Journal:  Toxicon       Date:  2014-06-17       Impact factor: 3.033

4.  Predictors of complications of snake envenomation in Cayenne, French Guiana, 2007-2015.

Authors:  Rémi Mutricy; Gérald Egmann; Christian Marty; Stéphanie Houcke; Antoine Adenis; Maylis Douine; Mathieu Nacher; Loïc Epelboin
Journal:  Intensive Care Med       Date:  2017-09-06       Impact factor: 17.440

Review 5.  Snakebite envenoming.

Authors:  José María Gutiérrez; Juan J Calvete; Abdulrazaq G Habib; Robert A Harrison; David J Williams; David A Warrell
Journal:  Nat Rev Dis Primers       Date:  2017-09-14       Impact factor: 52.329

6.  The role of fresh frozen plasma in reducing the volume of anti-snake venom in snakebite envenomation.

Authors:  Subraya Krishna Holla; Harish A Rao; Damodara Shenoy; Archith Boloor; Manaswitha Boyanagari
Journal:  Trop Doct       Date:  2018-02-02       Impact factor: 0.731

7.  Hemostasis dynamics during coagulopathy resulting from Echis envenomation.

Authors:  Georges Mion; Sébastien Larréché; Alain Benois; Fabrice Petitjeans; Marc Puidupin
Journal:  Toxicon       Date:  2013-09-24       Impact factor: 3.033

Review 8.  Snake antivenom for snake venom induced consumption coagulopathy.

Authors:  Kalana Maduwage; Nick A Buckley; H Janaka de Silva; David G Lalloo; Geoffrey K Isbister
Journal:  Cochrane Database Syst Rev       Date:  2015-06-09

9.  Snakebite-induced acute kidney injury in Latin America.

Authors:  Fábia M Oliveira Pinho; Luis Yu; Emmanuel A Burdmann
Journal:  Semin Nephrol       Date:  2008-07       Impact factor: 5.299

Review 10.  Snake bite.

Authors:  David A Warrell
Journal:  Lancet       Date:  2010-01-02       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.